Combinatorial antibodies against human malignant melanoma

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Human melanoma generally responds to immunotherapy, but identifying immunogenic melanoma antigens is crucial for effective active immunotherapy.
• Current challenges in melanoma treatment include a lack of detailed information on the immunogenicity of melanoma antigens in patients.

Purpose of the Study:

• To identify melanoma-associated antigens recognized by patients' B cells.
• To utilize antibody phage display for screening cell-surface-reactive antibodies against melanoma.

Main Methods:

• Employed antibody phage display to screen a cDNA library for antibodies recognizing melanoma cell surfaces.
• Displayed B-cell antibodies from a melanoma patient (in remission for over 7 years) as Fabs on filamentous phages.
• Selected phages by absorption to normal melanocytes, binding to and elution from melanoma cells, and reactivity with tunicamycin-treated melanoma cells, achieving >10^6-fold enrichment.

Main Results:

• Successfully identified melanoma-associated antigens recognized by B cells using the antibody phage display approach.
• One phage-Fab demonstrated binding to melanoma cells, other tumor cells, and some normal cells in cell lines and tissue sections.
• The antibody phage display method allowed direct screening without complex antibody production or purification.

Conclusions:

• Antibody phage display is an effective method for identifying tumor-specific antigens in melanoma.
• The identified antigens hold potential for developing targeted immunotherapies for melanoma.
• Further characterization of the binding specificities of the identified phage-Fab is warranted.